Diclofenaco Genfar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclofenaco Genfar

Quick Facts

Property Description
Active ingredient Diclofenac (e.g., Sodium or Potassium salt)
Form Tablets, capsules, gels, or solutions
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain, inflammation, and fever
Origin Synthetic, Phenylacetic acid derivative

What Type of Medicine is Diclofenaco Genfar?

Diclofenaco Genfar is a specific medication containing the active ingredient Diclofenac, which is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification places it among drugs that specifically target inflammatory processes. Diclofenac is a synthetic compound derived from the phenylacetic acid chemical family, distinguishing its structure from other analgesic agents. The product is typically a single-ingredient product, deriving its effect entirely from the Diclofenac entity itself. Its market positioning often focuses on providing an accessible option for managing acute discomfort.


Diclofenac's Composition and Available Forms

The core composition utilizes the Diclofenac substance, usually prepared as a salt (like Diclofenac sodium or potassium) to optimize stability and absorption. This salt is combined with appropriate excipients or a suitable base/vehicle tailored to the final preparation.

The medication is available in several dosage forms, which include oral preparations such as tablets and capsules, as well as preparations for topical application, such as gels. These forms allow for different routes of administration, enabling either systemic (oral) or localized (topical) application.


General Therapeutic Purpose of Diclofenaco Genfar

The general purpose of Diclofenaco Genfar is rooted in its established triple functional capacity: acting as an analgesic (pain reducer), an anti-inflammatory agent (reducing swelling), and an antipyretic (fever reducer).

Diclofenac modulates inflammatory and painful responses by inhibiting the synthesis of prostaglandins. This means the drug helps control symptoms by reducing the body's inflammatory chemical signals. By addressing these signals, the medication helps to mitigate general discomfort and lower elevated body temperature, providing comprehensive symptomatic relief.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

What side effects are possible with Diclofenaco Genfar?

Possible side effects and safety information

Official regulatory documentation structures the safety profile of Diclofenac (the active ingredient in Diclofenaco Genfar) by classifying adverse reactions based on the frequency of their occurrence and the body systems affected. These classifications ensure a neutral, standardized communication of documented risks.

Documented Adverse Reactions

Adverse reactions are formally grouped into categories consistent with international regulatory standards:

Classification System-Organ Class Examples
Common Headache, dizziness, and gastrointestinal disturbances (e.g., nausea, dyspepsia, abdominal pain).
Rare Hypersensitivity reactions, asthma, severe gastrointestinal complications (bleeding or perforation), and hepatitis.
Very Rare Severe skin reactions (e.g., Stevens-Johnson Syndrome) and acute renal failure.

Serious Safety Considerations

The prescribing information highlights specific serious adverse reactions. The medicine is associated with an increased risk of serious cardiovascular thrombotic events (such as myocardial infarction or stroke) and major gastrointestinal ulceration, bleeding, or perforation. These serious adverse events can occur at any point during treatment.

Safety Constraints and Special Populations

Specific safety considerations are noted for certain individuals. The risk of serious cardiovascular thrombotic events may increase with the duration of use and higher dosages. Older adults are at a greater documented risk for serious gastrointestinal consequences. The medication is formally contraindicated in individuals with existing active gastrointestinal bleeding or ulceration, a history of NSAID-related allergic reactions, and in the setting of severe heart failure or immediately following coronary artery bypass graft (CABG) surgery. Due to documented fetal risk, use is contraindicated during the last trimester of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Diclofenaco Genfar overdose involves the ingestion of amounts considered harmful, which can be very harmful in large quantities to both children and adults. Regulatory documentation indicates that a majority of acute NSAID overdose cases may remain asymptomatic or exhibit minor, temporary gastrointestinal issues. However, the potential for serious clinical sequelae is explicitly stated, particularly with higher doses.


Documented Manifestations and Severe Outcomes

The officially documented presentations of overdose affect the gastrointestinal (GI) and central nervous systems (CNS). Common symptoms include nausea, vomiting (potentially bloody), stomach pain (epigastric pain), drowsiness, dizziness, and lethargy. More severe outcomes listed in regulatory documents include seizures, coma, acute renal failure (kidney damage), and significant gastrointestinal bleeding, ulceration, or perforation, which can be fatal.


Required Emergency Actions

Seek immediate medical attention right away for any suspected overdose. Regulatory guidance explicitly states that individuals should call the local emergency number or Poison Control for instructions. Immediate medical help is also required for symptoms indicative of serious cardiovascular events, such as chest pain, shortness of breath, weakness or numbness in one part of the body, or slurred speech.

Management is described as symptomatic and supportive care as no specific antidote is known for Diclofenac. Supportive measures may include the administration of activated charcoal to reduce absorption and hospital monitoring of vital signs, including an Electrocardiogram (ECG) and renal function tests.

Therapeutic Uses of Diclofenaco Genfar

The therapeutic scope of Diclofenaco Genfar, which contains the active ingredient diclofenac, is considered relevant for easing symptoms related to inflammatory or irritative states and general physical discomfort. It is commonly used to help manage swelling (inflammation) and pain across various clinical contexts.

The medication is applied across domains where additional symptomatic support is needed for conditions where functional stability becomes affected, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also relevant when short-term symptomatic assistance is needed for acute episodes like soft tissue injuries, postoperative discomfort, and intense episodic pain, including Primary Dysmenorrhea, Renal Colic, and Gout flare-ups.

“It provides support that helps ease the overall symptom burden in situations where patients experience temporarily overwhelming discomfort.”

This focus on pain and inflammation contributes to improved day-to-day comfort during symptomatic periods and may assist with maintaining functional stability.


Quick Fact: Management of Pain and Inflammation Symptoms

Category Example Condition Symptom Clusters Addressed
Chronic Conditions Osteoarthritis, Rheumatoid Arthritis Joint pain, stiffness, swelling
Acute Symptomatic Conditions Sprains/Strains, Postoperative Pain Intense symptoms, swelling, tenderness
Episodic Symptomatic Conditions Primary Dysmenorrhea, Gout Heightened discomfort, localized symptoms, fever

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for Diclofenaco (Diclofenac), strictly based on governmental regulatory documents for systemic use.

Populations Prohibited from Use (Contraindications)

  • Allergy/Hypersensitivity: Individuals with a known allergy to diclofenac or any component of the formulation. This includes a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Cardiovascular: Patients undergoing pain treatment immediately before or after a coronary artery bypass graft (CABG) surgery.
  • Advanced Conditions (EMA/International): Patients with established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Pregnancy: Pregnant women starting at 30 weeks gestation (third trimester) due to the risk of premature closure of the fetal ductus arteriosus.

Populations Requiring Special Consideration

  • Age: Use in children younger than 12 years of age is generally not established for many oral formulations. Use in older adults requires caution due to a higher risk of age-related kidney or gastrointestinal problems.
  • Organ Function: Avoid use in patients with advanced renal disease or severe heart failure unless the expected benefits outweigh the risk of worsening the condition. Renal function monitoring is advised for patients with existing heart failure, renal, or hepatic impairment.
  • Cardiovascular Risk Factors: Individuals with significant risk factors for heart events (e.g., high blood pressure, high cholesterol, diabetes, smoking) should be treated only after careful consideration by a physician, and should use the lowest effective dose for the shortest duration.
  • Pregnancy/Lactation: Use during the second trimester (about 20 to 30 weeks gestation) is restricted, and it may not be safe to breastfeed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Diclofenac, the active ingredient in Diclofenaco Genfar, as stated in government regulatory sources. The interactions are primarily classified as pharmacodynamic effects or pharmacokinetic changes.

Formal Interaction Restrictions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including the analgesic dose of Aspirin (acetylsalicylic acid), is formally contraindicated due to the documented, severe risk of gastrointestinal bleeding.

Documented Pharmacokinetic Effects

Diclofenac metabolism involves the CYP2C9 enzyme system. Co-administration with the strong CYP2C9 inhibitor Voriconazole is documented to significantly increase the plasma concentration and total exposure ( AUC) of Diclofenac. Conversely, CYP2C9 inducers are anticipated to decrease exposure.

Pharmacodynamic and Clearance Interactions

Diclofenac co-administration may intensify risks or alter concentrations of other medications:

  • Bleeding Risk: Interactions with Anticoagulants, Antiplatelet Agents, SSRIs, and Corticosteroids are documented to increase the risk of serious bleeding events.
  • Renal Function: Combined use with ACE Inhibitors or ARBs may diminish their effect and is documented to potentially cause renal function deterioration, especially in elderly or volume-depleted patients.
  • Increased Drug Levels: Diclofenac can reduce the clearance of substances such as Lithium, Digoxin, Methotrexate, and Ciclosporin, leading to documented increases in their respective plasma concentrations.

Mechanism of Action

How Diclofenaco Genfar Works

Diclofenaco Genfar exerts its primary effect by acting as an inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This interaction modifies the initial molecular steps within the eicosanoid pathway, suppressing the synthesis of specific chemical mediators, primarily prostaglandins, that are implicated in the transmission and amplification of localized physiological signals.

The resulting blockade of prostaglandin synthesis directly modulates the chemical signaling in both inflammatory and nociception pathways. By reducing the presence of these signaling molecules in peripheral tissues, the drug results in reduced signaling output from inflammatory chemical mediators. The decrease in prostaglandin levels correlates with decreased vascular permeability and reduced activation threshold of nociceceptors.

A distinct mechanistic domain involves the drug's effect within the central nervous system, specifically the hypothalamus. Inhibition of prostaglandin synthesis in this area modulates the hypothalamic set-point for body temperature. This central action reduces the pyretic effect of prostaglandins, which constitutes a measurable physiological effect stemming from the central inhibition.

Dosage and Administration Information

How to Use Diclofenaco Genfar (Topical Administration)

The instructions for using diclofenac topical gel mandate application to the skin, with adherence to precise dosing and scheduling to ensure proper use, as documented in clinical standards.

Administration Guidelines

Administration Scope Rule for Use (1% Gel, Osteoarthritis)
Route of Administration Cutaneous (Topical use only) for adults.
Frequency Apply 4 times daily (QID).
Dosing (Upper Extremities) Apply 2 grams (g) to the entire affected area (hand, wrist, or elbow) QID. Do not exceed 8 g daily for any one joint.
Dosing (Lower Extremities) Apply 4 grams (g) to the entire affected area (foot, ankle, or knee) QID. Do not exceed 16 g daily for any one joint.
Total Maximum Dose The combined total dose across all treated joints must not exceed 32 g per day.

Procedural and Safety Steps

  • Dose Measurement: Use the dosing card provided in the product carton to measure the 2 g or 4 g dose accurately for each application.
  • Application Surface: Apply the gel only to intact, non-diseased skin. Do not use on open wounds, infections, or rashes.
  • Post-Application Care: Wash your hands completely after use, unless the treated area is the hand(s). If treating the hands, do not wash them for at least 1 hour after application.
  • Wait Time: Avoid showering or bathing for at least 1 hour after applying the gel. Avoid covering the treated area with clothing or gloves for at least 10 minutes to allow the gel to dry.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diclofenaco Genfar

The research surrounding Diclofenaco Genfar, which contains the active ingredient Diclofenac, consists of numerous clinical trials, systematic reviews, and meta-analyses. The purpose of these studies is to explore how the medication was studied for the specific types of physical discomfort and inflammation described. The information below describes the structure and focus of this evidence, rather than making claims about how the medication was studied for the study populations.


Evidence for Managing Chronic Pain and Inflammation

Studies examined adults diagnosed with chronic conditions like Osteoarthritis and Rheumatoid Arthritis. These studies, which include a large number of Randomized Controlled Trials (RCTs) and comprehensive reviews, explored chronic inflammatory conditions.

Researchers primarily monitored patient-reported outcomes describing perceived discomfort (pain scores) and outcomes reflecting daily functioning or activity level (physical function scores) in conditions marked by functional limitations. For inflammatory conditions such as Rheumatoid Arthritis, studies monitored changes in biomarkers like C-reactive protein (CRP) and ESR, which are outcomes linked to inflammatory or irritative states. These findings help contextualize how patients reported their experience during conditions involving periods of heightened symptoms.

Evidence for Acute Pain Relief

Research has explored the use of Diclofenac for managing episodic or acute changes in pain, such as following minor surgery, a sprain, or intense menstrual discomfort (Primary Dysmenorrhea). These studies are often designed as high-quality RCTs using single doses or very short treatment courses.

In research conducted during periods of increased symptom activity, the main outcomes monitored were related to the measured onset of change in patient-reported outcomes describing perceived discomfort and the percentage of participants who achieved a defined level of change in pain scores. Research exploring short-term symptom changes was observed in adult populations experiencing acute pain. Findings describe patterns observed in these studies, noting that the reported outcomes related to speed of action may differ based on the specific formulation, such as whether a fast-acting salt was used.

Understanding Research Gaps and Uncertainty

Despite the significant number of studies conducted over several decades, evidence highlights what is known—and what is still uncertain.

One of the key research limitation frames is that long-term effects are not fully established for many outcomes, especially the durability of functional changes over years. For acute pain, follow-up durations were limited and thus provide data primarily for short-term symptom changes.

Furthermore, evidence quality varies across studies, and the interpretation of findings often depends on the specific formulation (e.g., immediate-release vs. delayed-release). Research does not determine whether an individual will respond similarly to the patterns observed in the studies, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Safety review of diclofenac (Therapeutic Goods Administration - TGA)

Frequently Asked Questions (FAQ)

Common questions about Diclofenaco Genfar (FAQ)

Q: What is Diclofenaco Genfar used for besides pain?

Official regulatory documents indicate that diclofenac is used to treat pain, inflammation, and fever (antipyretic capacity). Official documents state it is indicated for managing the signs and symptoms of certain chronic conditions, such as osteoarthritis and rheumatoid arthritis, and for treating acute conditions like menstrual cramps.


Q: Is Diclofenaco Genfar safe to take with common vitamins?

Regulatory summaries primarily focus on interactions with other medicines, such as anticoagulants and other NSAIDs, and do not typically list common vitamins as formal drug-drug interactions. However, official guidance generally suggests informing a healthcare provider of all products being taken.


Q: Is Diclofenaco Genfar commonly prescribed for arthritis?

Official indications state that diclofenac is approved for the treatment of signs and symptoms related to osteoarthritis and rheumatoid arthritis.


Q: What is the role of Diclofenaco Genfar in treating menstrual cramps?

Certain oral formulations of diclofenac are formally indicated for the management of menstrual cramps, also known in medical terms as primary dysmenorrhea. Its role is based on its ability to reduce pain and inflammation.


Q: Does the drug's purpose change depending on the dosage prescribed?

The core purpose of diclofenac is always to reduce pain, inflammation, and fever. However, regulatory agencies provide formal indications for specific conditions (e.g., acute pain vs. arthritis) based on the studied formulation and dosage. This means the therapeutic use is often guided by the specific product and prescribed amount.


Q: Can women who are planning to become pregnant use Diclofenaco Genfar?

Official labeling advises that based on its mechanism of action, the use of diclofenac may potentially delay or prevent conception. Therefore, it is generally not recommended for use by women who are actively attempting to conceive. Official information advises that if a woman is experiencing difficulty conceiving, discontinuation of the drug should be considered.


Q: How long does it typically take for Diclofenaco Genfar to start working?

Official clinical pharmacology information for some oral forms suggests that measurable levels of the drug may appear in the bloodstream within 10 minutes of taking a dose, with peak concentrations achieved in about 1 hour. The time it takes for an individual to begin experiencing symptom changes can vary based on the specific formulation and the condition being treated.


Q: How long does the pain relief from Diclofenaco Genfar last?

The drug's half-life, which is the time it takes for half of the drug to be eliminated from the bloodstream, is approximately 1.9 to 2 hours. The actual duration of observed symptom relief for an individual is not precisely defined in regulatory texts and can vary, as it is influenced by the type of diclofenac formulation used and the nature of the discomfort.


Q: Is there a maximum number of days I can take Diclofenaco Genfar?

Regulatory guidelines emphasize using the lowest effective dose for the shortest duration necessary to minimize the risk of serious documented adverse events. Specific indications, such as for acute pain, may have official limits on the total number of days the medication can be taken.


Q: Can Diclofenaco Genfar affect my mood or sleep?

Official drug safety documentation lists several potential side effects involving the nervous system. Documented adverse reactions include experiences such as drowsiness, insomnia, nervousness, anxiety, depression, and dream abnormalities.


Q: Does Diclofenaco Genfar cause weight gain or loss?

Regulatory documents list weight changes as a documented, though generally infrequent, adverse reaction. Additionally, the drug has been associated with fluid retention and swelling (edema), which may lead to secondary weight changes.


Q: What happens if I miss a dose of Diclofenaco Genfar?

Patient information generally describes a procedure where if a dose is missed, it can be taken when remembered, but only if it is not nearly time for the next scheduled dose, in which case the missed dose is skipped. This description of a procedure is not personalized instruction.


Q: Is there any research on the long-term effects of taking Diclofenaco Genfar?

Regulatory warnings specifically state that the risk of serious adverse events, including cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal events (like bleeding), is documented to increase with the duration of use. This connection is a major focus in long-term safety evaluations.


Q: Does Diclofenaco Genfar interact with herbal supplements?

Official drug interaction lists are generally silent on most common herbal supplements. However, official information advises informing a healthcare provider of all herbal products being used, as some, such as ginkgo biloba, have been suggested to potentially increase the risk of bleeding when taken with diclofenac.


Q: Why do some people experience ringing in the ears when taking Diclofenaco Genfar?

Official safety documents list tinnitus (a sensation of ringing or buzzing in the ears) as a documented adverse reaction that has been reported by some users.


Q: Does the Genfar brand of Diclofenaco have a coating or special formulation?

The active ingredient, diclofenac, is commonly available in different formulations, including those with special coatings, such as enteric-coated or delayed-release tablets. These coatings are added to protect the stomach. While the specific brand name is not referenced in general regulatory documents, the availability of these specific forms is common for the active substance.


Q: Can Diclofenaco Genfar be crushed or chewed?

Many oral forms of diclofenac are manufactured as enteric-coated or delayed-release tablets. The official standard for these products typically states that they should not be crushed, chewed, or cut, as altering the tablet can destroy the coating intended to protect the stomach and can lead to unintended changes in how the drug is released into the body.


Q: Are there any specific foods that interact with Diclofenaco Genfar?

Official clinical pharmacology sections note that for some oral formulations, taking the medication with food can cause a delay in absorption and a reduction in the peak concentration of the drug in the bloodstream. For certain fast-acting formulations, a specific recommendation to take them on an empty stomach may be provided.


Q: Can Diclofenaco Genfar cause sensitivity to the sun?

Photosensitivity, which is an increased sensitivity of the skin to sunlight or ultraviolet (UV) light, is listed in regulatory texts as a documented, though rare, adverse reaction.


Q: Can Diclofenaco Genfar affect my blood sugar levels?

Official safety documentation for the drug lists hyperglycemia (elevated blood sugar) as an infrequent, documented adverse reaction reported in official sources.


Q: What should I do if I think I'm experiencing a side effect from Diclofenaco Genfar?

Official patient counseling information advises that individuals experiencing concerning symptoms should contact a healthcare provider, particularly for signs of serious adverse events like chest pain, trouble breathing, or black/tarry stools, or to seek emergency help for signs of a severe allergic reaction.


Q: Are there specific symptoms that signal a need to stop taking Diclofenaco Genfar?

Official warnings specify that the medication is to be discontinued and professional medical help sought immediately for symptoms of serious conditions, such as severe skin rash, signs of liver injury (like yellowing of the skin or eyes), or signs of gastrointestinal bleeding.


Q: What is the difference between Diclofenaco Genfar and a steroid?

Diclofenaco Genfar, which contains the active ingredient diclofenac, is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its classification specifically indicates that it does not belong to the class of drugs known as corticosteroids, which are a separate group of anti-inflammatory medications.


Q: Does Diclofenaco Genfar have any restrictions regarding driving or operating machinery?

Official labeling advises that if patients experience documented adverse effects such as dizziness, vertigo, drowsiness, or visual disturbances, they should refrain from activities like driving or operating machinery until these effects subside.


Q: Can Diclofenaco Genfar cause changes in vision?

Official safety documentation lists blurred vision as a documented adverse reaction in the comprehensive list of effects reported in official sources.


Q: Can Diclofenaco Genfar be used for tension headaches?

The general purpose of the drug is pain relief, and some formulations are specifically indicated for certain types of headaches, such as migraine headaches. However, official regulatory indications for diclofenac do not formally list tension headaches as an approved use.

How should Diclofenaco Genfar be stored and disposed of?

Storage and Disposal of Diclofenac Sodium

Official regulatory guidelines mandate specific conditions for storing and disposing of diclofenac sodium, the active ingredient in Diclofenaco Genfar, to maintain product stability and safety.


Storage Requirements

Requirement Specification
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from freezing, excessive heat, moisture, and direct light.
Packaging Keep the medicine in its original, tightly closed container.
Child Safety Store all forms of the drug out of the sight and reach of children.

Disposal Instructions

Unused or expired product must be disposed of in accordance with local regulations. To protect the environment, do not dispose of the medication by flushing it down the toilet or pouring it into a drain. Utilize official medicine take-back programs or consult a healthcare professional for specific disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclofenaco Genfar found in:

A-Z Index: